Phase 2 Monoclonal Gammopathy of Renal Significance Clinical Trials
2 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 2
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Monoclonal Gammopathy of Renal Significance
Peking University People's Hospital20 enrolled3 locationsNCT06418477